According to Analysists-Upcoming Presentation Would Be Whole Different Thing Compared to Previous Ones!!
VTVT has been working on a different delivery method to refine the previous study and this different options could change
the way in which Alzheimer’s is treated. Load up this cheap shares as much as you can NOW, Once they release a final data
VTVT will hit $50~$100.
----------------------
vTv Therapeutics to Deliver Two Presentations at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
BUSINESS WIRE 10:30 AM ET 10/16/2018
Results of the Azeliragon Phase 3 STEADFAST Trial to be Presented during Oral Session
Subgroup Data Discussing the Effect of Azeliragon in Patients with Dementia and Diabetes to be Presented during Poster Session
HIGH POINT, N.C.--(BUSINESS WIRE)-- vTv Therapeutics Inc.(VTVT) , a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, today announced that it will deliver an oral presentation and present a poster at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) conference on October 24-27, 2018 in Barcelona, Spain.
The oral presentation will detail the results from the phase 3 STEADFAST study of azeliragon in patients with mild Alzheimer’s disease. Details of the oral presentation are listed below:
Oral Presentation Title: “Safety and efficacy results from the phase 3, multicenter, 18-month STEADFAST trial of azeliragon in patients with mild Alzheimer’s disease”
Date and Time: Fri., Oct. 26, 2018 at 3 p.m. CEST (9 a.m. EST)
In addition, a subgroup analysis from the company’s STEADFAST trial will be presented as a poster. Details of the poster presentation are listed below:
Late-Breaking Poster Title: “Is RAGE the missing link between diabetes and dementia? Results from a subgroup analysis of the STEADFAST trial”
Poster Number: LBP18
Category: Clinical Trials: Results
Date and Time: Wed., Oct. 24, 2018 (3 p.m. CEST) through Sat., Oct. 27, 2018 (3 p.m. CEST)
About vTv Therapeutics(VTVT)
vTv Therapeutics Inc. (VTVT) is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and diabetes as well as treatment of inflammatory disorders.
About STEADFAST
The STEADFAST study, two independent and identical randomized, double-blind, placebo-controlled Phase 3 trials (Part A and Part B), was designed to investigate the safety and efficacy of azeliragon as a potential treatment for patients with mild Alzheimer’s disease. The 18-month study targeted enrollment of 800 patients (400 in each trial). The first trial enrolled patients in the United States and Canada who had a clinical diagnosis of mild Alzheimer’s disease and an MRI consistent with this diagnosis. Enrollment of the second trial included study sites in the United Kingdom, Ireland, Australia, New Zealand and South Africa.
